Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP530955.RAjYKUN2YGIk493OvVeJvy54Sc3_52i5QdkTpUmALKmtc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP530955.RAjYKUN2YGIk493OvVeJvy54Sc3_52i5QdkTpUmALKmtc130_assertion type Assertion NP530955.RAjYKUN2YGIk493OvVeJvy54Sc3_52i5QdkTpUmALKmtc130_head.
- NP530955.RAjYKUN2YGIk493OvVeJvy54Sc3_52i5QdkTpUmALKmtc130_assertion description "[We investigate here the mechanisms by which in vivo abrogation of leptin effects protects SJL/J mice from proteolipid protein peptide PLP(139-151)-induced EAE, an animal model of MS. Blockade of leptin with anti-leptin Abs or with a soluble mouse leptin receptor chimera (ObR:Fc), either before or after onset of EAE, improved clinical score, slowed disease progression, reduced disease relapses, inhibited PLP(139-151)-specific T cell proliferation, and switched cytokine secretion toward a Th2/regulatory profile.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP530955.RAjYKUN2YGIk493OvVeJvy54Sc3_52i5QdkTpUmALKmtc130_provenance.
- NP530955.RAjYKUN2YGIk493OvVeJvy54Sc3_52i5QdkTpUmALKmtc130_assertion evidence source_evidence_literature NP530955.RAjYKUN2YGIk493OvVeJvy54Sc3_52i5QdkTpUmALKmtc130_provenance.
- NP530955.RAjYKUN2YGIk493OvVeJvy54Sc3_52i5QdkTpUmALKmtc130_assertion SIO_000772 16410832 NP530955.RAjYKUN2YGIk493OvVeJvy54Sc3_52i5QdkTpUmALKmtc130_provenance.
- NP530955.RAjYKUN2YGIk493OvVeJvy54Sc3_52i5QdkTpUmALKmtc130_assertion wasDerivedFrom befree-2016 NP530955.RAjYKUN2YGIk493OvVeJvy54Sc3_52i5QdkTpUmALKmtc130_provenance.
- NP530955.RAjYKUN2YGIk493OvVeJvy54Sc3_52i5QdkTpUmALKmtc130_assertion wasGeneratedBy ECO_0000203 NP530955.RAjYKUN2YGIk493OvVeJvy54Sc3_52i5QdkTpUmALKmtc130_provenance.